ILiAD Biotechnologies
PrivateLast Round
Series B
Feb 10, 2026
Est. Valuation
$176M
Total Funding Raised
$219.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ILiAD Biotechnologies is a biotechnology company that develops a medical vaccine aimed at preventing and treating diseases caused by Bordetella pertussis by inducing the immune system to produce protective antibodies against infections like whooping cough.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ILiAD Biotechnologies Comparables
Compare ILiAD Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Codagenix | 77% | |
| Sanofi | 76% | |
| CyanVac LLC | 71% |
ILiAD Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| Series D | Sep 6, 2022 | ||||
| Grant | Apr 26, 2022 | ||||
| Convertible Debt | Mar 12, 2021 | ||||
| Series C | Dec 19, 2018 | ||||
Grant | Jul 5, 2017 |
Key People
Founding team and executive leadership
ILiAD Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| National Institute of Allergy and Infectious Diseases | Grant |
| Knott Partners, LP | Series D |
| Network-1 Technologies | Convertible Debt, Series C |
| SDS Capital Group | Series C |
| Seedlings Life Science Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 38% MoM.
- Jul 25, 2026
Monthly visitors increased 44% MoM, reaching 2.2K.
Recent news
Latest coverage and updates
- hiresAug 11, 2026
ILiAD Biotechnologies, Inc. hired Jim Wassil as board on Aug 11th '26.
- is_developingAug 11, 2026
ILiAD Biotechnologies, Inc. is developing BPZE1.
- hiresAug 11, 2026
ILiAD Biotechnologies, Inc. hired Bill Warren as board on Aug 11th '26.
- hiresAug 11, 2026
ILiAD Biotechnologies, Inc. hired Antony Blanc as Chief Business Officer on Aug 11th '26.
ILiAD Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ILiAD Biotechnologies's valuation, stock price, and market status.
Is ILiAD Biotechnologies a public or private company?
ILiAD Biotechnologies is a private company.
What is the current stock price of ILiAD Biotechnologies?
ILiAD Biotechnologies is a private company with no public stock price. No recent secondary market data is available.
How much is ILiAD Biotechnologies worth (valuation)?
ILiAD Biotechnologies's valuation is estimated at $176.0M based on funding round data.
Can I buy ILiAD Biotechnologies stock?
ILiAD Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ILiAD Biotechnologies's last funding round?
ILiAD Biotechnologies's most recent funding round was Series B on March 12, 2021.
Who are the main investors in ILiAD Biotechnologies?
Key investors in ILiAD Biotechnologies include RA Capital Management, Knott Partners, LP, Network-1 Technologies, SDS Capital Partners.
Will ILiAD Biotechnologies IPO soon?
No public IPO plans have been announced for ILiAD Biotechnologies.
How can I track ILiAD Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ILiAD Biotechnologies's secondary market activity and sign up for updates.